Výsledky vyhledávání - "Klaus Peter, Kammerer"

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study

Autor: Holger Rosenbrock, Viktoria Moschetti, Glen Wunderlich, Michael Desch, Karl-Heinz Liesenfeld, Sven Wind, Klaus-Peter Kammerer, Sophia Goetz

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics

Background and objectives Schizophrenia and Alzheimer’s disease are characterised by glutamatergic pathway abnormalities related to N-methyl-d-aspartate (NMDA) receptor hypofunction and cognitive impairment. Glycine is an NMDA receptor co-agonist;

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7981ec9505b7b5d5b0a245304e1a06d
https://doi.org/10.1007/s13318-017-0440-z

Zobrazit plný text záznamu

Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study

Autor: Rüdiger Koenen, Klaus Peter Kammerer, Kristell Marzin, Mabrouk Elgadi, Fenglei Huang, Natalja Strelkowa, Anne-Marie Quinson, Sebastian Haertter

Publikováno v: The Journal of Clinical Pharmacology. 57:1305-1314

Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus protease. It inhibits multiple cytochrome P-450 enzymes and multiple membrane transporters. The objective of this study was to evaluate the effect of steady-state falda

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::511013f139cb2c8bb00656fd358edd59
https://doi.org/10.1002/jcph.931

Zobrazit plný text záznamu

Who is a ‘healthy subject’?—consensus results on pivotal eligibility criteria for clinical trials

Autor: Karin Goehler, Thomas Sudhop, Martin Coenen, Klaus Peter Kammerer, Klaus Francke, Georg Wensing, Hildegard Sourgens, Jens Rengelshausen, Frank Donath, Mario Iovino, Kerstin Breithaupt-Groegler, Reinhard Schinzel, Gerd Mikus, Christoph Coch, Katharina Erb-Zohar

Publikováno v: European Journal of Clinical Pharmacology

Introduction/Methods A discussion forum was hosted by the German not-for-profit Association for Applied Human Pharmacology (AGAH e.V.) to critically review key eligibility criteria and stopping rules for clinical trials with healthy subjects, enrolli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feabe534c46e9ba3d2232d9f80e5e871
http://europepmc.org/articles/PMC5350217

Zobrazit plný text záznamu

Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open-label, crossover phase 1 study

Autor: Michaela Gutacker, Klaus Peter Kammerer, Selma Calcagnile, Corinna Lanzarotti, Verena Jakob-Rodamer, Wolfgang Timmer

Publikováno v: Clinical Pharmacology in Drug Development. 4:377-386

Antiemetic treatment compliance is important to prevent chemotherapy-induced nausea and vomiting, a feared chemotherapy side effect. NEPA, a new oral fixed combination of netupitant, a highly selective NK1 receptor antagonist (RA), and palonosetron,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5393ebf4eb04faaae428cf8945250ffa
https://doi.org/10.1002/cpdd.192

Zobrazit plný text záznamu

Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study

Autor: Fenglei, Huang, Kristell, Marzin, Rüdiger, Koenen, Klaus Peter, Kammerer, Natalja, Strelkowa, Mabrouk, Elgadi, Anne-Marie, Quinson, Sebastian, Haertter

Publikováno v: Journal of clinical pharmacology. 57(10)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f94feaa39a538049c67cd236536f5fbe
https://pubmed.ncbi.nlm.nih.gov/28513969

Zobrazit plný text záznamu

Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives

Autor: Corinna Lanzarotti, Wolfgang Timmer, Klaus Peter Kammerer, Anders Henriksson, Giorgia Rossi, Selma Calcagnile

Publikováno v: Supportive Care in Cancer. 21:2879-2887

Neurokinin-1 receptor antagonists (NK1 RAs) are commonly coadministered with a 5-HT3 RA such as palonosetron to prevent nausea and vomiting induced by chemotherapy. Netupitant, a new highly selective NK1 RA, is both a substrate for and a moderate inh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ab118aedaf3b00dc9a37e7b718ae096b
https://doi.org/10.1007/s00520-013-1857-9

Zobrazit plný text záznamu

Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open-label, crossover phase 1 study

Autor: Selma, Calcagnile, Corinna, Lanzarotti, Michaela, Gutacker, Verena, Jakob-Rodamer, Klaus, Peter Kammerer, Wolfgang, Timmer

Publikováno v: Clinical pharmacology in drug development. 4(5)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::24772e11a787bb84abc0b0f937348871
https://pubmed.ncbi.nlm.nih.gov/27137147

Zobrazit plný text záznamu

Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives

Autor: Selma, Calcagnile, Corinna, Lanzarotti, Giorgia, Rossi, Anders, Henriksson, Klaus Peter, Kammerer, Wolfgang, Timmer

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 21(10)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::64116ab89bc88ffd27454a030c5a23ca
https://pubmed.ncbi.nlm.nih.gov/23748441

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání